NCT01517854 (RePo1) is a Phase 2 clinical trial of Sildenafil in Portopulmonary Hypertension, sponsored by University Health Network, Toronto.

Who is sponsoring NCT01517854?

NCT01517854 is sponsored by University Health Network, Toronto.

What drugs are being tested in NCT01517854?

Interventions in NCT01517854: Sildenafil, Placebo.

What condition does NCT01517854 study?

NCT01517854 studies Portopulmonary Hypertension.

Is NCT01517854 still recruiting?

NCT01517854 is currently terminated. Last updated 27 September 2019.

Last reviewed 2019-09-27 · How we verify

NCT01517854: RePo1

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Revatio Portal-Pulmonary Arterial Hypertension Trial

Terminated Phase 2 Last updated 27 September 2019

What this trial tests

Phase 2 trial testing Sildenafil in Portopulmonary Hypertension in 12 participants. Terminated before completion.

Timeline

14 November 2012

Primary endpoint
30 October 2017

14 May 2019

Quick facts

Lead sponsor	University Health Network, Toronto
Phase	Phase 2
Status	Terminated
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	treatment
Enrollment	12
Start date	14 November 2012
Primary completion	30 October 2017
Estimated completion	14 May 2019
Sites	3 locations across Canada

Drugs / interventions tested

Sildenafil (sildenafil) — full drug profile →
Placebo

Conditions studied

Portopulmonary Hypertension — all drugs for Portopulmonary Hypertension →

Sponsor

University Health Network, Toronto

Who can join

Adults 18 to 75, any sex, with Portopulmonary Hypertension. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The investigators propose the first prospective, double blind, randomized controlled trial of treatment for pulmonary arterial hypertension (PAH) related to underlying portal hypertension. Specifically the investigators will evaluate the potential efficacy and safety of sildenafil (Revatio) in a 16 week blinded, multicentre study.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Sildenafil

Trials testing the same drug.

NCT07039760 — Asciminib With or Without Sildenafil for Brain Tumors · EARLY_PHASE1 · not yet recruiting
NCT06800092 — Sildenafil to Prevent and Reduce Cancer Related Cognitive Impairment · Phase 2, PHASE3 · not yet recruiting
NCT06954597 — Safety and Tolerability of TOP-N53 Applied on Digital Ulcers in Patients With Systemic Sclerosis · Phase 2 · recruiting
NCT06778330 — The Effect of Combination of Dapagliflozin and Sildenafil in Treatment of Heart Failure Patients With Secondary Pulmonar · NA · completed
NCT06875258 — PEnile ReHABilitation After Nerve Sparing Robot-assisted Radical Prostatectomy for Prostate Cancer 2.0 (PEHAB-II) · Phase 4 · recruiting

Other University Health Network, Toronto trials

Trials by the same sponsor.

NCT06831032 — Elective Adaptive Radiation With SBRT for Improved DurabilitY of Response · NA · recruiting
NCT06634056 — Pneumonitis Prevention Protocol Using Pentoxifylline and α-tocopherol In Stage III Non-Small Cell Lung Cancer Patients U · Phase 2 · not yet recruiting
NCT06836726 — Clinical Trial to Test Efficacy of Targeting Hypoxia Combined With ARSI After First-line ARSI Therapy for Castrate Resis · Phase 2 · not yet recruiting
NCT07515651 — Molecular Imaging Informed Radiation Dose Escalation to Sites of Recurrent Disease and De-escalation to Uninvolved Areas · Phase 2 · not yet recruiting
NCT07509450 — Fecal Microbiota Transplantation in Patients Undergoing Chimeric Antigen Receptor T-cell Therapy and Allogeneic Stem Cel · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT01517854 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University Health Network, Toronto
Last refreshed: 27 September 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01517854.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing